nodes	percent_of_prediction	percent_of_DWPC	metapath
Naproxen—PTGS1—esophageal cancer	0.334	0.636	CbGaD
Naproxen—PTGS2—esophageal cancer	0.191	0.364	CbGaD
Naproxen—PTGS2—Cisplatin—esophageal cancer	0.059	0.27	CbGbCtD
Naproxen—SLCO1A2—Methotrexate—esophageal cancer	0.0468	0.214	CbGbCtD
Naproxen—CYP2C9—Capecitabine—esophageal cancer	0.0398	0.183	CbGbCtD
Naproxen—SLC22A6—Methotrexate—esophageal cancer	0.0284	0.13	CbGbCtD
Naproxen—ALB—Methotrexate—esophageal cancer	0.0242	0.111	CbGbCtD
Naproxen—CYP2C9—Cisplatin—esophageal cancer	0.0201	0.0919	CbGbCtD
Naproxen—Indomethacin—GLO1—esophageal cancer	0.00161	0.228	CrCbGaD
Naproxen—Nabumetone—PTGS1—esophageal cancer	0.000652	0.0921	CrCbGaD
Naproxen—Carprofen—PTGS1—esophageal cancer	0.000622	0.0879	CrCbGaD
Naproxen—Ibuprofen—BCL2—esophageal cancer	0.00047	0.0664	CrCbGaD
Naproxen—Suprofen—PTGS1—esophageal cancer	0.000384	0.0543	CrCbGaD
Naproxen—Nabumetone—PTGS2—esophageal cancer	0.000373	0.0527	CrCbGaD
Naproxen—Carprofen—PTGS2—esophageal cancer	0.000356	0.0502	CrCbGaD
Naproxen—Fenoprofen—PTGS1—esophageal cancer	0.000331	0.0468	CrCbGaD
Naproxen—Indomethacin—ABCC2—esophageal cancer	0.000323	0.0456	CrCbGaD
Naproxen—Cardiac disorder—Cisplatin—esophageal cancer	0.000256	0.00196	CcSEcCtD
Naproxen—Abdominal distension—Capecitabine—esophageal cancer	0.000256	0.00196	CcSEcCtD
Naproxen—Dysphagia—Capecitabine—esophageal cancer	0.000254	0.00195	CcSEcCtD
Naproxen—Influenza—Capecitabine—esophageal cancer	0.000254	0.00195	CcSEcCtD
Naproxen—Asthma—Capecitabine—esophageal cancer	0.000254	0.00195	CcSEcCtD
Naproxen—Thrombophlebitis—Methotrexate—esophageal cancer	0.000253	0.00194	CcSEcCtD
Naproxen—Diabetes mellitus—Methotrexate—esophageal cancer	0.000252	0.00193	CcSEcCtD
Naproxen—Polyuria—Methotrexate—esophageal cancer	0.000249	0.00191	CcSEcCtD
Naproxen—Photosensitivity—Methotrexate—esophageal cancer	0.000249	0.00191	CcSEcCtD
Naproxen—Immune system disorder—Cisplatin—esophageal cancer	0.000249	0.00191	CcSEcCtD
Naproxen—Mediastinal disorder—Cisplatin—esophageal cancer	0.000249	0.00191	CcSEcCtD
Naproxen—Angina pectoris—Capecitabine—esophageal cancer	0.000247	0.0019	CcSEcCtD
Naproxen—Arrhythmia—Cisplatin—esophageal cancer	0.000246	0.00189	CcSEcCtD
Naproxen—Indomethacin—PTGS1—esophageal cancer	0.000244	0.0345	CrCbGaD
Naproxen—Bronchitis—Capecitabine—esophageal cancer	0.000244	0.00187	CcSEcCtD
Naproxen—Alopecia—Cisplatin—esophageal cancer	0.000244	0.00187	CcSEcCtD
Naproxen—Abdominal discomfort—Capecitabine—esophageal cancer	0.000244	0.00187	CcSEcCtD
Naproxen—Hepatic failure—Methotrexate—esophageal cancer	0.000244	0.00187	CcSEcCtD
Naproxen—Pancytopenia—Capecitabine—esophageal cancer	0.000241	0.00185	CcSEcCtD
Naproxen—Malnutrition—Cisplatin—esophageal cancer	0.00024	0.00184	CcSEcCtD
Naproxen—Erythema—Cisplatin—esophageal cancer	0.00024	0.00184	CcSEcCtD
Naproxen—Dysuria—Capecitabine—esophageal cancer	0.000238	0.00182	CcSEcCtD
Naproxen—Flatulence—Cisplatin—esophageal cancer	0.000237	0.00181	CcSEcCtD
Naproxen—Dermatitis exfoliative—Methotrexate—esophageal cancer	0.000232	0.00178	CcSEcCtD
Naproxen—Photosensitivity reaction—Capecitabine—esophageal cancer	0.000232	0.00178	CcSEcCtD
Naproxen—Visual disturbance—Methotrexate—esophageal cancer	0.000231	0.00177	CcSEcCtD
Naproxen—Muscle spasms—Cisplatin—esophageal cancer	0.000231	0.00177	CcSEcCtD
Naproxen—Weight decreased—Capecitabine—esophageal cancer	0.00023	0.00176	CcSEcCtD
Naproxen—Hyperglycaemia—Capecitabine—esophageal cancer	0.000229	0.00176	CcSEcCtD
Naproxen—Pneumonia—Capecitabine—esophageal cancer	0.000228	0.00175	CcSEcCtD
Naproxen—Vision blurred—Cisplatin—esophageal cancer	0.000226	0.00173	CcSEcCtD
Naproxen—Anaphylactoid reaction—Methotrexate—esophageal cancer	0.000226	0.00173	CcSEcCtD
Naproxen—Depression—Capecitabine—esophageal cancer	0.000226	0.00173	CcSEcCtD
Naproxen—Tremor—Cisplatin—esophageal cancer	0.000225	0.00172	CcSEcCtD
Naproxen—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	0.000225	0.00172	CcSEcCtD
Naproxen—Acute coronary syndrome—Capecitabine—esophageal cancer	0.000223	0.00171	CcSEcCtD
Naproxen—Ill-defined disorder—Cisplatin—esophageal cancer	0.000223	0.00171	CcSEcCtD
Naproxen—Renal failure—Capecitabine—esophageal cancer	0.000223	0.00171	CcSEcCtD
Naproxen—Myocardial infarction—Capecitabine—esophageal cancer	0.000222	0.0017	CcSEcCtD
Naproxen—Neuropathy peripheral—Capecitabine—esophageal cancer	0.000222	0.0017	CcSEcCtD
Naproxen—Anaemia—Cisplatin—esophageal cancer	0.000222	0.0017	CcSEcCtD
Naproxen—Stomatitis—Capecitabine—esophageal cancer	0.000221	0.00169	CcSEcCtD
Naproxen—Jaundice—Capecitabine—esophageal cancer	0.000221	0.00169	CcSEcCtD
Naproxen—Conjunctivitis—Capecitabine—esophageal cancer	0.00022	0.00169	CcSEcCtD
Naproxen—Urinary tract infection—Capecitabine—esophageal cancer	0.00022	0.00169	CcSEcCtD
Naproxen—Suprofen—PTGS2—esophageal cancer	0.00022	0.031	CrCbGaD
Naproxen—Osteoarthritis—Methotrexate—esophageal cancer	0.000219	0.00168	CcSEcCtD
Naproxen—Malaise—Cisplatin—esophageal cancer	0.000217	0.00166	CcSEcCtD
Naproxen—Flurbiprofen—PTGS1—esophageal cancer	0.000216	0.0305	CrCbGaD
Naproxen—Haematuria—Capecitabine—esophageal cancer	0.000216	0.00166	CcSEcCtD
Naproxen—Leukopenia—Cisplatin—esophageal cancer	0.000215	0.00165	CcSEcCtD
Naproxen—Hepatobiliary disease—Capecitabine—esophageal cancer	0.000214	0.00164	CcSEcCtD
Naproxen—Epistaxis—Capecitabine—esophageal cancer	0.000214	0.00164	CcSEcCtD
Naproxen—Agranulocytosis—Capecitabine—esophageal cancer	0.000211	0.00162	CcSEcCtD
Naproxen—Convulsion—Cisplatin—esophageal cancer	0.000208	0.00159	CcSEcCtD
Naproxen—AKR1C3—bronchus—esophageal cancer	0.000208	0.0895	CbGeAlD
Naproxen—Mood swings—Methotrexate—esophageal cancer	0.000207	0.00159	CcSEcCtD
Naproxen—Myalgia—Cisplatin—esophageal cancer	0.000204	0.00157	CcSEcCtD
Naproxen—Haemoglobin—Capecitabine—esophageal cancer	0.000204	0.00157	CcSEcCtD
Naproxen—Rhinitis—Capecitabine—esophageal cancer	0.000204	0.00156	CcSEcCtD
Naproxen—Anxiety—Cisplatin—esophageal cancer	0.000204	0.00156	CcSEcCtD
Naproxen—Haemorrhage—Capecitabine—esophageal cancer	0.000203	0.00156	CcSEcCtD
Naproxen—Hepatitis—Capecitabine—esophageal cancer	0.000203	0.00156	CcSEcCtD
Naproxen—AKR1C3—smooth muscle tissue—esophageal cancer	0.000203	0.0875	CbGeAlD
Naproxen—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000203	0.00156	CcSEcCtD
Naproxen—Liver function test abnormal—Methotrexate—esophageal cancer	0.000202	0.00155	CcSEcCtD
Naproxen—Discomfort—Cisplatin—esophageal cancer	0.000202	0.00155	CcSEcCtD
Naproxen—Pharyngitis—Capecitabine—esophageal cancer	0.000202	0.00155	CcSEcCtD
Naproxen—Urinary tract disorder—Capecitabine—esophageal cancer	0.000201	0.00154	CcSEcCtD
Naproxen—Oedema peripheral—Capecitabine—esophageal cancer	0.0002	0.00154	CcSEcCtD
Naproxen—Connective tissue disorder—Capecitabine—esophageal cancer	0.0002	0.00153	CcSEcCtD
Naproxen—Urethral disorder—Capecitabine—esophageal cancer	0.000199	0.00153	CcSEcCtD
Naproxen—Breast disorder—Methotrexate—esophageal cancer	0.000198	0.00152	CcSEcCtD
Naproxen—Toxic epidermal necrolysis—Methotrexate—esophageal cancer	0.000197	0.00151	CcSEcCtD
Naproxen—Anaphylactic shock—Cisplatin—esophageal cancer	0.000196	0.0015	CcSEcCtD
Naproxen—Oedema—Cisplatin—esophageal cancer	0.000196	0.0015	CcSEcCtD
Naproxen—Visual impairment—Capecitabine—esophageal cancer	0.000196	0.0015	CcSEcCtD
Naproxen—Ketoprofen—PTGS1—esophageal cancer	0.000196	0.0276	CrCbGaD
Naproxen—Infection—Cisplatin—esophageal cancer	0.000195	0.00149	CcSEcCtD
Naproxen—Ibuprofen—PTGS1—esophageal cancer	0.000192	0.0272	CrCbGaD
Naproxen—Erythema multiforme—Capecitabine—esophageal cancer	0.000192	0.00147	CcSEcCtD
Naproxen—Nervous system disorder—Cisplatin—esophageal cancer	0.000192	0.00147	CcSEcCtD
Naproxen—Thrombocytopenia—Cisplatin—esophageal cancer	0.000192	0.00147	CcSEcCtD
Naproxen—Tachycardia—Cisplatin—esophageal cancer	0.000191	0.00147	CcSEcCtD
Naproxen—Skin disorder—Cisplatin—esophageal cancer	0.00019	0.00146	CcSEcCtD
Naproxen—Eye disorder—Capecitabine—esophageal cancer	0.00019	0.00146	CcSEcCtD
Naproxen—Tinnitus—Capecitabine—esophageal cancer	0.00019	0.00145	CcSEcCtD
Naproxen—Hyperhidrosis—Cisplatin—esophageal cancer	0.000189	0.00145	CcSEcCtD
Naproxen—Fenoprofen—PTGS2—esophageal cancer	0.000189	0.0268	CrCbGaD
Naproxen—Asthma—Methotrexate—esophageal cancer	0.000189	0.00145	CcSEcCtD
Naproxen—Cardiac disorder—Capecitabine—esophageal cancer	0.000189	0.00145	CcSEcCtD
Naproxen—Eosinophilia—Methotrexate—esophageal cancer	0.000187	0.00144	CcSEcCtD
Naproxen—Anorexia—Cisplatin—esophageal cancer	0.000187	0.00143	CcSEcCtD
Naproxen—AKR1C3—trachea—esophageal cancer	0.000186	0.0803	CbGeAlD
Naproxen—Pancreatitis—Methotrexate—esophageal cancer	0.000185	0.00142	CcSEcCtD
Naproxen—Angiopathy—Capecitabine—esophageal cancer	0.000185	0.00141	CcSEcCtD
Naproxen—Immune system disorder—Capecitabine—esophageal cancer	0.000184	0.00141	CcSEcCtD
Naproxen—Mediastinal disorder—Capecitabine—esophageal cancer	0.000183	0.0014	CcSEcCtD
Naproxen—Hypotension—Cisplatin—esophageal cancer	0.000183	0.0014	CcSEcCtD
Naproxen—Chills—Capecitabine—esophageal cancer	0.000182	0.0014	CcSEcCtD
Naproxen—Arrhythmia—Capecitabine—esophageal cancer	0.000182	0.00139	CcSEcCtD
Naproxen—Abdominal discomfort—Methotrexate—esophageal cancer	0.000181	0.00139	CcSEcCtD
Naproxen—Alopecia—Capecitabine—esophageal cancer	0.00018	0.00138	CcSEcCtD
Naproxen—Pancytopenia—Methotrexate—esophageal cancer	0.00018	0.00138	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000179	0.00137	CcSEcCtD
Naproxen—Mental disorder—Capecitabine—esophageal cancer	0.000178	0.00137	CcSEcCtD
Naproxen—Erythema—Capecitabine—esophageal cancer	0.000177	0.00136	CcSEcCtD
Naproxen—Malnutrition—Capecitabine—esophageal cancer	0.000177	0.00136	CcSEcCtD
Naproxen—Dysuria—Methotrexate—esophageal cancer	0.000177	0.00136	CcSEcCtD
Naproxen—Paraesthesia—Cisplatin—esophageal cancer	0.000176	0.00135	CcSEcCtD
Naproxen—Dyspnoea—Cisplatin—esophageal cancer	0.000175	0.00134	CcSEcCtD
Naproxen—Flatulence—Capecitabine—esophageal cancer	0.000174	0.00134	CcSEcCtD
Naproxen—UGT2B7—digestive system—esophageal cancer	0.000174	0.075	CbGeAlD
Naproxen—Photosensitivity reaction—Methotrexate—esophageal cancer	0.000173	0.00132	CcSEcCtD
Naproxen—Decreased appetite—Cisplatin—esophageal cancer	0.00017	0.00131	CcSEcCtD
Naproxen—Muscle spasms—Capecitabine—esophageal cancer	0.00017	0.0013	CcSEcCtD
Naproxen—Pneumonia—Methotrexate—esophageal cancer	0.00017	0.0013	CcSEcCtD
Naproxen—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000169	0.0013	CcSEcCtD
Naproxen—Drowsiness—Methotrexate—esophageal cancer	0.000169	0.00129	CcSEcCtD
Naproxen—Depression—Methotrexate—esophageal cancer	0.000168	0.00129	CcSEcCtD
Naproxen—Pain—Cisplatin—esophageal cancer	0.000168	0.00128	CcSEcCtD
Naproxen—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	0.000167	0.00128	CcSEcCtD
Naproxen—Vision blurred—Capecitabine—esophageal cancer	0.000167	0.00128	CcSEcCtD
Naproxen—Tremor—Capecitabine—esophageal cancer	0.000166	0.00127	CcSEcCtD
Naproxen—Renal failure—Methotrexate—esophageal cancer	0.000166	0.00127	CcSEcCtD
Naproxen—Stomatitis—Methotrexate—esophageal cancer	0.000164	0.00126	CcSEcCtD
Naproxen—Ill-defined disorder—Capecitabine—esophageal cancer	0.000164	0.00126	CcSEcCtD
Naproxen—Conjunctivitis—Methotrexate—esophageal cancer	0.000164	0.00126	CcSEcCtD
Naproxen—Anaemia—Capecitabine—esophageal cancer	0.000164	0.00125	CcSEcCtD
Naproxen—Sweating—Methotrexate—esophageal cancer	0.000162	0.00124	CcSEcCtD
Naproxen—Feeling abnormal—Cisplatin—esophageal cancer	0.000162	0.00124	CcSEcCtD
Naproxen—Haematuria—Methotrexate—esophageal cancer	0.000161	0.00123	CcSEcCtD
Naproxen—Malaise—Capecitabine—esophageal cancer	0.00016	0.00122	CcSEcCtD
Naproxen—Hepatobiliary disease—Methotrexate—esophageal cancer	0.000159	0.00122	CcSEcCtD
Naproxen—Epistaxis—Methotrexate—esophageal cancer	0.000159	0.00122	CcSEcCtD
Naproxen—Vertigo—Capecitabine—esophageal cancer	0.000159	0.00122	CcSEcCtD
Naproxen—Syncope—Capecitabine—esophageal cancer	0.000159	0.00122	CcSEcCtD
Naproxen—Leukopenia—Capecitabine—esophageal cancer	0.000158	0.00121	CcSEcCtD
Naproxen—Agranulocytosis—Methotrexate—esophageal cancer	0.000157	0.00121	CcSEcCtD
Naproxen—Palpitations—Capecitabine—esophageal cancer	0.000156	0.0012	CcSEcCtD
Naproxen—Loss of consciousness—Capecitabine—esophageal cancer	0.000156	0.00119	CcSEcCtD
Naproxen—Body temperature increased—Cisplatin—esophageal cancer	0.000155	0.00119	CcSEcCtD
Naproxen—Cough—Capecitabine—esophageal cancer	0.000154	0.00118	CcSEcCtD
Naproxen—Hypertension—Capecitabine—esophageal cancer	0.000153	0.00117	CcSEcCtD
Naproxen—Haemoglobin—Methotrexate—esophageal cancer	0.000152	0.00117	CcSEcCtD
Naproxen—Hepatitis—Methotrexate—esophageal cancer	0.000151	0.00116	CcSEcCtD
Naproxen—Haemorrhage—Methotrexate—esophageal cancer	0.000151	0.00116	CcSEcCtD
Naproxen—Myalgia—Capecitabine—esophageal cancer	0.000151	0.00115	CcSEcCtD
Naproxen—Arthralgia—Capecitabine—esophageal cancer	0.000151	0.00115	CcSEcCtD
Naproxen—Chest pain—Capecitabine—esophageal cancer	0.000151	0.00115	CcSEcCtD
Naproxen—Pharyngitis—Methotrexate—esophageal cancer	0.00015	0.00115	CcSEcCtD
Naproxen—Anxiety—Capecitabine—esophageal cancer	0.00015	0.00115	CcSEcCtD
Naproxen—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.00015	0.00115	CcSEcCtD
Naproxen—Urinary tract disorder—Methotrexate—esophageal cancer	0.00015	0.00115	CcSEcCtD
Naproxen—Discomfort—Capecitabine—esophageal cancer	0.000149	0.00114	CcSEcCtD
Naproxen—Urethral disorder—Methotrexate—esophageal cancer	0.000148	0.00114	CcSEcCtD
Naproxen—UGT1A1—digestive system—esophageal cancer	0.000148	0.0637	CbGeAlD
Naproxen—Dry mouth—Capecitabine—esophageal cancer	0.000147	0.00113	CcSEcCtD
Naproxen—Visual impairment—Methotrexate—esophageal cancer	0.000146	0.00112	CcSEcCtD
Naproxen—Confusional state—Capecitabine—esophageal cancer	0.000146	0.00112	CcSEcCtD
Naproxen—Oedema—Capecitabine—esophageal cancer	0.000144	0.00111	CcSEcCtD
Naproxen—Hypersensitivity—Cisplatin—esophageal cancer	0.000144	0.00111	CcSEcCtD
Naproxen—Infection—Capecitabine—esophageal cancer	0.000144	0.0011	CcSEcCtD
Naproxen—Erythema multiforme—Methotrexate—esophageal cancer	0.000143	0.0011	CcSEcCtD
Naproxen—Shock—Capecitabine—esophageal cancer	0.000142	0.00109	CcSEcCtD
Naproxen—Nervous system disorder—Capecitabine—esophageal cancer	0.000142	0.00109	CcSEcCtD
Naproxen—Eye disorder—Methotrexate—esophageal cancer	0.000141	0.00108	CcSEcCtD
Naproxen—Thrombocytopenia—Capecitabine—esophageal cancer	0.000141	0.00108	CcSEcCtD
Naproxen—Tinnitus—Methotrexate—esophageal cancer	0.000141	0.00108	CcSEcCtD
Naproxen—Tachycardia—Capecitabine—esophageal cancer	0.000141	0.00108	CcSEcCtD
Naproxen—Asthenia—Cisplatin—esophageal cancer	0.000141	0.00108	CcSEcCtD
Naproxen—Cardiac disorder—Methotrexate—esophageal cancer	0.00014	0.00108	CcSEcCtD
Naproxen—Skin disorder—Capecitabine—esophageal cancer	0.00014	0.00108	CcSEcCtD
Naproxen—Indomethacin—PTGS2—esophageal cancer	0.00014	0.0197	CrCbGaD
Naproxen—Hyperhidrosis—Capecitabine—esophageal cancer	0.00014	0.00107	CcSEcCtD
Naproxen—Anorexia—Capecitabine—esophageal cancer	0.000138	0.00106	CcSEcCtD
Naproxen—Angiopathy—Methotrexate—esophageal cancer	0.000137	0.00105	CcSEcCtD
Naproxen—Immune system disorder—Methotrexate—esophageal cancer	0.000137	0.00105	CcSEcCtD
Naproxen—Mediastinal disorder—Methotrexate—esophageal cancer	0.000136	0.00105	CcSEcCtD
Naproxen—Chills—Methotrexate—esophageal cancer	0.000136	0.00104	CcSEcCtD
Naproxen—Hypotension—Capecitabine—esophageal cancer	0.000135	0.00103	CcSEcCtD
Naproxen—Diarrhoea—Cisplatin—esophageal cancer	0.000134	0.00103	CcSEcCtD
Naproxen—AKR1C3—lung—esophageal cancer	0.000134	0.0577	CbGeAlD
Naproxen—Alopecia—Methotrexate—esophageal cancer	0.000134	0.00103	CcSEcCtD
Naproxen—Mental disorder—Methotrexate—esophageal cancer	0.000133	0.00102	CcSEcCtD
Naproxen—Erythema—Methotrexate—esophageal cancer	0.000132	0.00101	CcSEcCtD
Naproxen—Malnutrition—Methotrexate—esophageal cancer	0.000132	0.00101	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000132	0.00101	CcSEcCtD
Naproxen—Insomnia—Capecitabine—esophageal cancer	0.000131	0.001	CcSEcCtD
Naproxen—Paraesthesia—Capecitabine—esophageal cancer	0.00013	0.000994	CcSEcCtD
Naproxen—Dyspnoea—Capecitabine—esophageal cancer	0.000129	0.000987	CcSEcCtD
Naproxen—Dyspepsia—Capecitabine—esophageal cancer	0.000127	0.000975	CcSEcCtD
Naproxen—Decreased appetite—Capecitabine—esophageal cancer	0.000126	0.000962	CcSEcCtD
Naproxen—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000125	0.000956	CcSEcCtD
Naproxen—Vomiting—Cisplatin—esophageal cancer	0.000125	0.000955	CcSEcCtD
Naproxen—Fatigue—Capecitabine—esophageal cancer	0.000125	0.000955	CcSEcCtD
Naproxen—Vision blurred—Methotrexate—esophageal cancer	0.000124	0.000952	CcSEcCtD
Naproxen—Rash—Cisplatin—esophageal cancer	0.000124	0.000947	CcSEcCtD
Naproxen—Flurbiprofen—PTGS2—esophageal cancer	0.000124	0.0175	CrCbGaD
Naproxen—Constipation—Capecitabine—esophageal cancer	0.000124	0.000947	CcSEcCtD
Naproxen—Pain—Capecitabine—esophageal cancer	0.000124	0.000947	CcSEcCtD
Naproxen—Dermatitis—Cisplatin—esophageal cancer	0.000123	0.000946	CcSEcCtD
Naproxen—Ill-defined disorder—Methotrexate—esophageal cancer	0.000122	0.000937	CcSEcCtD
Naproxen—Anaemia—Methotrexate—esophageal cancer	0.000122	0.000933	CcSEcCtD
Naproxen—Feeling abnormal—Capecitabine—esophageal cancer	0.000119	0.000912	CcSEcCtD
Naproxen—Malaise—Methotrexate—esophageal cancer	0.000119	0.000911	CcSEcCtD
Naproxen—Indomethacin—ABCB1—esophageal cancer	0.000119	0.0168	CrCbGaD
Naproxen—Vertigo—Methotrexate—esophageal cancer	0.000118	0.000907	CcSEcCtD
Naproxen—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000118	0.000905	CcSEcCtD
Naproxen—Leukopenia—Methotrexate—esophageal cancer	0.000118	0.000904	CcSEcCtD
Naproxen—Nausea—Cisplatin—esophageal cancer	0.000116	0.000892	CcSEcCtD
Naproxen—Cough—Methotrexate—esophageal cancer	0.000115	0.000881	CcSEcCtD
Naproxen—Urticaria—Capecitabine—esophageal cancer	0.000115	0.00088	CcSEcCtD
Naproxen—Abdominal pain—Capecitabine—esophageal cancer	0.000114	0.000875	CcSEcCtD
Naproxen—Body temperature increased—Capecitabine—esophageal cancer	0.000114	0.000875	CcSEcCtD
Naproxen—Convulsion—Methotrexate—esophageal cancer	0.000114	0.000875	CcSEcCtD
Naproxen—Arthralgia—Methotrexate—esophageal cancer	0.000112	0.00086	CcSEcCtD
Naproxen—Myalgia—Methotrexate—esophageal cancer	0.000112	0.00086	CcSEcCtD
Naproxen—Chest pain—Methotrexate—esophageal cancer	0.000112	0.00086	CcSEcCtD
Naproxen—Ketoprofen—PTGS2—esophageal cancer	0.000112	0.0158	CrCbGaD
Naproxen—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000111	0.000854	CcSEcCtD
Naproxen—Discomfort—Methotrexate—esophageal cancer	0.000111	0.000849	CcSEcCtD
Naproxen—Ibuprofen—PTGS2—esophageal cancer	0.00011	0.0155	CrCbGaD
Naproxen—Confusional state—Methotrexate—esophageal cancer	0.000108	0.000831	CcSEcCtD
Naproxen—Anaphylactic shock—Methotrexate—esophageal cancer	0.000108	0.000824	CcSEcCtD
Naproxen—Infection—Methotrexate—esophageal cancer	0.000107	0.000819	CcSEcCtD
Naproxen—Hypersensitivity—Capecitabine—esophageal cancer	0.000106	0.000816	CcSEcCtD
Naproxen—Nervous system disorder—Methotrexate—esophageal cancer	0.000105	0.000808	CcSEcCtD
Naproxen—Thrombocytopenia—Methotrexate—esophageal cancer	0.000105	0.000807	CcSEcCtD
Naproxen—Skin disorder—Methotrexate—esophageal cancer	0.000104	0.000801	CcSEcCtD
Naproxen—Hyperhidrosis—Methotrexate—esophageal cancer	0.000104	0.000797	CcSEcCtD
Naproxen—Asthenia—Capecitabine—esophageal cancer	0.000104	0.000794	CcSEcCtD
Naproxen—Anorexia—Methotrexate—esophageal cancer	0.000103	0.000786	CcSEcCtD
Naproxen—Pruritus—Capecitabine—esophageal cancer	0.000102	0.000783	CcSEcCtD
Naproxen—Hypotension—Methotrexate—esophageal cancer	0.0001	0.00077	CcSEcCtD
Naproxen—SLCO1A2—digestive system—esophageal cancer	0.0001	0.0432	CbGeAlD
Naproxen—Diarrhoea—Capecitabine—esophageal cancer	9.89e-05	0.000758	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Methotrexate—esophageal cancer	9.8e-05	0.000751	CcSEcCtD
Naproxen—Insomnia—Methotrexate—esophageal cancer	9.73e-05	0.000745	CcSEcCtD
Naproxen—Paraesthesia—Methotrexate—esophageal cancer	9.66e-05	0.00074	CcSEcCtD
Naproxen—Dyspnoea—Methotrexate—esophageal cancer	9.59e-05	0.000735	CcSEcCtD
Naproxen—Somnolence—Methotrexate—esophageal cancer	9.56e-05	0.000733	CcSEcCtD
Naproxen—Dizziness—Capecitabine—esophageal cancer	9.55e-05	0.000732	CcSEcCtD
Naproxen—Dyspepsia—Methotrexate—esophageal cancer	9.47e-05	0.000726	CcSEcCtD
Naproxen—Ibuprofen—ABCB1—esophageal cancer	9.36e-05	0.0132	CrCbGaD
Naproxen—Decreased appetite—Methotrexate—esophageal cancer	9.35e-05	0.000716	CcSEcCtD
Naproxen—Gastrointestinal disorder—Methotrexate—esophageal cancer	9.29e-05	0.000712	CcSEcCtD
Naproxen—Fatigue—Methotrexate—esophageal cancer	9.27e-05	0.000711	CcSEcCtD
Naproxen—Pain—Methotrexate—esophageal cancer	9.2e-05	0.000705	CcSEcCtD
Naproxen—Vomiting—Capecitabine—esophageal cancer	9.19e-05	0.000704	CcSEcCtD
Naproxen—AKR1C3—lymph node—esophageal cancer	9.16e-05	0.0395	CbGeAlD
Naproxen—Rash—Capecitabine—esophageal cancer	9.11e-05	0.000698	CcSEcCtD
Naproxen—Dermatitis—Capecitabine—esophageal cancer	9.1e-05	0.000697	CcSEcCtD
Naproxen—Headache—Capecitabine—esophageal cancer	9.05e-05	0.000694	CcSEcCtD
Naproxen—Feeling abnormal—Methotrexate—esophageal cancer	8.86e-05	0.000679	CcSEcCtD
Naproxen—Gastrointestinal pain—Methotrexate—esophageal cancer	8.79e-05	0.000674	CcSEcCtD
Naproxen—Nausea—Capecitabine—esophageal cancer	8.58e-05	0.000658	CcSEcCtD
Naproxen—Urticaria—Methotrexate—esophageal cancer	8.54e-05	0.000655	CcSEcCtD
Naproxen—Abdominal pain—Methotrexate—esophageal cancer	8.5e-05	0.000652	CcSEcCtD
Naproxen—Body temperature increased—Methotrexate—esophageal cancer	8.5e-05	0.000652	CcSEcCtD
Naproxen—SLCO1A2—lung—esophageal cancer	8.37e-05	0.036	CbGeAlD
Naproxen—Hypersensitivity—Methotrexate—esophageal cancer	7.92e-05	0.000607	CcSEcCtD
Naproxen—Asthenia—Methotrexate—esophageal cancer	7.72e-05	0.000591	CcSEcCtD
Naproxen—Pruritus—Methotrexate—esophageal cancer	7.61e-05	0.000583	CcSEcCtD
Naproxen—PTGS1—epithelium—esophageal cancer	7.46e-05	0.0321	CbGeAlD
Naproxen—Diarrhoea—Methotrexate—esophageal cancer	7.36e-05	0.000564	CcSEcCtD
Naproxen—PTGS1—smooth muscle tissue—esophageal cancer	7.19e-05	0.031	CbGeAlD
Naproxen—PTGS2—epithelium—esophageal cancer	7.13e-05	0.0307	CbGeAlD
Naproxen—Dizziness—Methotrexate—esophageal cancer	7.11e-05	0.000545	CcSEcCtD
Naproxen—PTGS2—bronchus—esophageal cancer	7.02e-05	0.0303	CbGeAlD
Naproxen—PTGS2—smooth muscle tissue—esophageal cancer	6.87e-05	0.0296	CbGeAlD
Naproxen—Vomiting—Methotrexate—esophageal cancer	6.84e-05	0.000524	CcSEcCtD
Naproxen—Rash—Methotrexate—esophageal cancer	6.78e-05	0.00052	CcSEcCtD
Naproxen—Dermatitis—Methotrexate—esophageal cancer	6.78e-05	0.000519	CcSEcCtD
Naproxen—Headache—Methotrexate—esophageal cancer	6.74e-05	0.000516	CcSEcCtD
Naproxen—PTGS1—trachea—esophageal cancer	6.6e-05	0.0284	CbGeAlD
Naproxen—CYP1A2—digestive system—esophageal cancer	6.55e-05	0.0282	CbGeAlD
Naproxen—Nausea—Methotrexate—esophageal cancer	6.39e-05	0.00049	CcSEcCtD
Naproxen—PTGS2—trachea—esophageal cancer	6.31e-05	0.0272	CbGeAlD
Naproxen—CYP2C9—digestive system—esophageal cancer	6.22e-05	0.0268	CbGeAlD
Naproxen—ALB—lymph node—esophageal cancer	5.69e-05	0.0245	CbGeAlD
Naproxen—PTGS1—digestive system—esophageal cancer	5.68e-05	0.0245	CbGeAlD
Naproxen—CYP1A2—lung—esophageal cancer	5.47e-05	0.0236	CbGeAlD
Naproxen—PTGS2—digestive system—esophageal cancer	5.42e-05	0.0234	CbGeAlD
Naproxen—PTGS1—lung—esophageal cancer	4.74e-05	0.0204	CbGeAlD
Naproxen—PTGS2—lung—esophageal cancer	4.53e-05	0.0195	CbGeAlD
Naproxen—PTGS1—lymph node—esophageal cancer	3.24e-05	0.014	CbGeAlD
Naproxen—PTGS2—lymph node—esophageal cancer	3.1e-05	0.0134	CbGeAlD
Naproxen—UGT2B7—Metabolism—ABCB1—esophageal cancer	1.87e-05	0.000161	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—CYP2A6—esophageal cancer	1.87e-05	0.000161	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—KDR—esophageal cancer	1.87e-05	0.00016	CbGpPWpGaD
Naproxen—AKR1C3—Disease—PTGS2—esophageal cancer	1.86e-05	0.00016	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—CYP19A1—esophageal cancer	1.86e-05	0.00016	CbGpPWpGaD
Naproxen—PTGS1—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	1.86e-05	0.00016	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—ALDOB—esophageal cancer	1.86e-05	0.000159	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—CYP1B1—esophageal cancer	1.85e-05	0.000159	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—ADH1B—esophageal cancer	1.82e-05	0.000157	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—CA2—esophageal cancer	1.82e-05	0.000156	CbGpPWpGaD
Naproxen—ALB—Metabolism—ADH1B—esophageal cancer	1.81e-05	0.000156	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	1.79e-05	0.000154	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—GAPDH—esophageal cancer	1.79e-05	0.000153	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	1.79e-05	0.000153	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	1.78e-05	0.000153	CbGpPWpGaD
Naproxen—ALB—Transmembrane transport of small molecules—HMOX1—esophageal cancer	1.77e-05	0.000152	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—ENO1—esophageal cancer	1.77e-05	0.000152	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—CRABP1—esophageal cancer	1.77e-05	0.000152	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—NOTCH1—esophageal cancer	1.76e-05	0.000151	CbGpPWpGaD
Naproxen—PTGS2—Disease—B2M—esophageal cancer	1.75e-05	0.000151	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PSME1—esophageal cancer	1.75e-05	0.00015	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PSME2—esophageal cancer	1.75e-05	0.00015	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—TYMP—esophageal cancer	1.74e-05	0.00015	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—CYP19A1—esophageal cancer	1.74e-05	0.000149	CbGpPWpGaD
Naproxen—ALB—Metabolism—TYMP—esophageal cancer	1.73e-05	0.000149	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	1.73e-05	0.000148	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—NOS3—esophageal cancer	1.71e-05	0.000147	CbGpPWpGaD
Naproxen—ALB—Transmembrane transport of small molecules—ABCB1—esophageal cancer	1.7e-05	0.000146	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—CA1—esophageal cancer	1.7e-05	0.000146	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—SLC10A2—esophageal cancer	1.7e-05	0.000146	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—HMOX1—esophageal cancer	1.7e-05	0.000146	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—CYP26A1—esophageal cancer	1.7e-05	0.000146	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—ADH7—esophageal cancer	1.69e-05	0.000145	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PLCE1—esophageal cancer	1.69e-05	0.000145	CbGpPWpGaD
Naproxen—ALB—Metabolism—CYP26A1—esophageal cancer	1.69e-05	0.000145	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—GNG7—esophageal cancer	1.69e-05	0.000145	CbGpPWpGaD
Naproxen—PTGS2—Disease—ENO1—esophageal cancer	1.68e-05	0.000144	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	1.67e-05	0.000144	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.67e-05	0.000143	CbGpPWpGaD
Naproxen—PTGS2—Disease—PSME1—esophageal cancer	1.66e-05	0.000142	CbGpPWpGaD
Naproxen—PTGS2—Disease—PSME2—esophageal cancer	1.66e-05	0.000142	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—ALOX15—esophageal cancer	1.65e-05	0.000142	CbGpPWpGaD
Naproxen—ALB—Metabolism—ALOX15—esophageal cancer	1.64e-05	0.000141	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—ABCB1—esophageal cancer	1.63e-05	0.00014	CbGpPWpGaD
Naproxen—AKR1C3—Disease—CDKN1A—esophageal cancer	1.63e-05	0.00014	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—CREBBP—esophageal cancer	1.59e-05	0.000137	CbGpPWpGaD
Naproxen—PTGS2—Disease—CALR—esophageal cancer	1.59e-05	0.000136	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—HMOX1—esophageal cancer	1.59e-05	0.000136	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—ALDH2—esophageal cancer	1.58e-05	0.000136	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—GSTO1—esophageal cancer	1.58e-05	0.000135	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—TPI1—esophageal cancer	1.58e-05	0.000135	CbGpPWpGaD
Naproxen—ALB—Metabolism—TPI1—esophageal cancer	1.57e-05	0.000135	CbGpPWpGaD
Naproxen—ALB—Metabolism—GSTO1—esophageal cancer	1.57e-05	0.000135	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—PTGS2—esophageal cancer	1.56e-05	0.000134	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—CA2—esophageal cancer	1.56e-05	0.000134	CbGpPWpGaD
Naproxen—AKR1C3—Disease—EP300—esophageal cancer	1.55e-05	0.000133	CbGpPWpGaD
Naproxen—PTGS2—Disease—FBXW7—esophageal cancer	1.54e-05	0.000132	CbGpPWpGaD
Naproxen—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	1.53e-05	0.000131	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—ABCB1—esophageal cancer	1.52e-05	0.000131	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	1.52e-05	0.000131	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—ALDOB—esophageal cancer	1.51e-05	0.00013	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—CYP1B1—esophageal cancer	1.51e-05	0.000129	CbGpPWpGaD
Naproxen—ALB—Metabolism—ALDOB—esophageal cancer	1.5e-05	0.000129	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—GSTT1—esophageal cancer	1.5e-05	0.000129	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—CYP2A6—esophageal cancer	1.49e-05	0.000127	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—ADH1B—esophageal cancer	1.48e-05	0.000127	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	1.48e-05	0.000127	CbGpPWpGaD
Naproxen—ALB—Hemostasis—NOS2—esophageal cancer	1.46e-05	0.000126	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—GAPDH—esophageal cancer	1.46e-05	0.000125	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PLCE1—esophageal cancer	1.45e-05	0.000124	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—ADH7—esophageal cancer	1.45e-05	0.000124	CbGpPWpGaD
Naproxen—ALB—Metabolism—GAPDH—esophageal cancer	1.45e-05	0.000124	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—CRABP1—esophageal cancer	1.44e-05	0.000124	CbGpPWpGaD
Naproxen—ALB—Metabolism—CRABP1—esophageal cancer	1.43e-05	0.000123	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	1.43e-05	0.000123	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—NOS3—esophageal cancer	1.43e-05	0.000123	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—TYMP—esophageal cancer	1.42e-05	0.000122	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—CYP19A1—esophageal cancer	1.42e-05	0.000122	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—PTGS1—esophageal cancer	1.41e-05	0.000121	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—ENO1—esophageal cancer	1.41e-05	0.000121	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—PSME2—esophageal cancer	1.39e-05	0.000119	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—PSME1—esophageal cancer	1.39e-05	0.000119	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—CYP26A1—esophageal cancer	1.38e-05	0.000118	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—GNG7—esophageal cancer	1.37e-05	0.000118	CbGpPWpGaD
Naproxen—ALB—Metabolism—GNG7—esophageal cancer	1.36e-05	0.000117	CbGpPWpGaD
Naproxen—AKR1C3—Disease—MYC—esophageal cancer	1.35e-05	0.000116	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—ALOX15—esophageal cancer	1.35e-05	0.000115	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—ERBB2—esophageal cancer	1.34e-05	0.000115	CbGpPWpGaD
Naproxen—AKR1C3—Disease—EGFR—esophageal cancer	1.32e-05	0.000113	CbGpPWpGaD
Naproxen—ALB—Hemostasis—CREBBP—esophageal cancer	1.31e-05	0.000113	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—EP300—esophageal cancer	1.3e-05	0.000111	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—HMOX1—esophageal cancer	1.29e-05	0.000111	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—ALDH2—esophageal cancer	1.29e-05	0.00011	CbGpPWpGaD
Naproxen—ALB—Platelet activation, signaling and aggregation—PIK3CA—esophageal cancer	1.29e-05	0.00011	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—TPI1—esophageal cancer	1.28e-05	0.00011	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—GSTO1—esophageal cancer	1.28e-05	0.00011	CbGpPWpGaD
Naproxen—ALB—Metabolism—ALDH2—esophageal cancer	1.28e-05	0.00011	CbGpPWpGaD
Naproxen—PTGS1—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.27e-05	0.000109	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—ADH1B—esophageal cancer	1.27e-05	0.000109	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—CREBBP—esophageal cancer	1.25e-05	0.000108	CbGpPWpGaD
Naproxen—PTGS2—Disease—TGFBR2—esophageal cancer	1.24e-05	0.000107	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—ABCB1—esophageal cancer	1.24e-05	0.000107	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.23e-05	0.000106	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—ALDOB—esophageal cancer	1.23e-05	0.000106	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—GSTT1—esophageal cancer	1.22e-05	0.000105	CbGpPWpGaD
Naproxen—ALB—Metabolism—GSTT1—esophageal cancer	1.22e-05	0.000104	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—TYMP—esophageal cancer	1.21e-05	0.000104	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—CYP2A6—esophageal cancer	1.21e-05	0.000104	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	1.2e-05	0.000103	CbGpPWpGaD
Naproxen—ALB—Metabolism—CYP2A6—esophageal cancer	1.2e-05	0.000103	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—CYP1B1—esophageal cancer	1.2e-05	0.000103	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	1.2e-05	0.000103	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—GAPDH—esophageal cancer	1.18e-05	0.000102	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—CCND1—esophageal cancer	1.18e-05	0.000101	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—CYP26A1—esophageal cancer	1.18e-05	0.000101	CbGpPWpGaD
Naproxen—PTGS2—Disease—SMAD4—esophageal cancer	1.18e-05	0.000101	CbGpPWpGaD
Naproxen—ALB—Hemostasis—NOS3—esophageal cancer	1.18e-05	0.000101	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—CRABP1—esophageal cancer	1.17e-05	0.000101	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—ALOX15—esophageal cancer	1.15e-05	9.87e-05	CbGpPWpGaD
Naproxen—AKR1C3—Disease—PIK3CA—esophageal cancer	1.15e-05	9.85e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PTGS1—esophageal cancer	1.15e-05	9.83e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—ENO1—esophageal cancer	1.15e-05	9.83e-05	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—CDKN1A—esophageal cancer	1.14e-05	9.8e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—ENO1—esophageal cancer	1.14e-05	9.78e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—PTGS1—esophageal cancer	1.14e-05	9.78e-05	CbGpPWpGaD
Naproxen—ALB—Transmembrane transport of small molecules—CREBBP—esophageal cancer	1.14e-05	9.77e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PSME1—esophageal cancer	1.13e-05	9.69e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PSME2—esophageal cancer	1.13e-05	9.69e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—CYP19A1—esophageal cancer	1.13e-05	9.66e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—PSME2—esophageal cancer	1.12e-05	9.63e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—PSME1—esophageal cancer	1.12e-05	9.63e-05	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—NOS3—esophageal cancer	1.12e-05	9.63e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—GNG7—esophageal cancer	1.12e-05	9.58e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—GSTO1—esophageal cancer	1.1e-05	9.41e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—TPI1—esophageal cancer	1.1e-05	9.41e-05	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—CREBBP—esophageal cancer	1.09e-05	9.36e-05	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—EP300—esophageal cancer	1.09e-05	9.32e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—ALDOB—esophageal cancer	1.05e-05	9.02e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—ALDH2—esophageal cancer	1.05e-05	8.98e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—HMOX1—esophageal cancer	1.03e-05	8.82e-05	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—PTGS2—esophageal cancer	1.03e-05	8.81e-05	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—CREBBP—esophageal cancer	1.02e-05	8.74e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—GAPDH—esophageal cancer	1.01e-05	8.69e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.01e-05	8.65e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—CRABP1—esophageal cancer	1e-05	8.61e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—GSTT1—esophageal cancer	9.95e-06	8.54e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—ABCB1—esophageal cancer	9.86e-06	8.46e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	9.86e-06	8.46e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—CYP2A6—esophageal cancer	9.84e-06	8.44e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	9.8e-06	8.41e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	9.8e-06	8.41e-05	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—NOS3—esophageal cancer	9.77e-06	8.38e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—CYP1B1—esophageal cancer	9.74e-06	8.36e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—CYP1B1—esophageal cancer	9.69e-06	8.31e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—HIF1A—esophageal cancer	9.63e-06	8.27e-05	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—PIK3CA—esophageal cancer	9.61e-06	8.25e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—GNG7—esophageal cancer	9.54e-06	8.19e-05	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—MYC—esophageal cancer	9.46e-06	8.12e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	9.39e-06	8.06e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—ENO1—esophageal cancer	9.32e-06	8e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PTGS1—esophageal cancer	9.32e-06	8e-05	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—EGFR—esophageal cancer	9.26e-06	7.94e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PSME2—esophageal cancer	9.19e-06	7.89e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PSME1—esophageal cancer	9.19e-06	7.89e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—CYP19A1—esophageal cancer	9.16e-06	7.86e-05	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—NOS3—esophageal cancer	9.12e-06	7.82e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—CYP19A1—esophageal cancer	9.11e-06	7.82e-05	CbGpPWpGaD
Naproxen—ALB—Hemostasis—EP300—esophageal cancer	8.96e-06	7.69e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—ALDH2—esophageal cancer	8.94e-06	7.67e-05	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—PTGS2—esophageal cancer	8.94e-06	7.67e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—NOS2—esophageal cancer	8.76e-06	7.52e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—NOTCH1—esophageal cancer	8.68e-06	7.45e-05	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—EP300—esophageal cancer	8.53e-06	7.32e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—GSTT1—esophageal cancer	8.5e-06	7.3e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—CYP2A6—esophageal cancer	8.41e-06	7.21e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	8.37e-06	7.19e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—HMOX1—esophageal cancer	8.36e-06	7.17e-05	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—PTGS2—esophageal cancer	8.34e-06	7.16e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—HMOX1—esophageal cancer	8.31e-06	7.13e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—CREBBP—esophageal cancer	8.3e-06	7.12e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	8.2e-06	7.04e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	8.15e-06	7e-05	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—PIK3CA—esophageal cancer	8.03e-06	6.89e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	8.02e-06	6.89e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—ABCB1—esophageal cancer	8.02e-06	6.89e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—ABCB1—esophageal cancer	7.98e-06	6.85e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PTGS1—esophageal cancer	7.97e-06	6.84e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—ENO1—esophageal cancer	7.97e-06	6.84e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—CYP1B1—esophageal cancer	7.93e-06	6.8e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—CREBBP—esophageal cancer	7.87e-06	6.75e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PSME2—esophageal cancer	7.85e-06	6.74e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PSME1—esophageal cancer	7.85e-06	6.74e-05	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—TP53—esophageal cancer	7.77e-06	6.67e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—CYP19A1—esophageal cancer	7.45e-06	6.4e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	7.45e-06	6.4e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—NOS3—esophageal cancer	7.43e-06	6.38e-05	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—EP300—esophageal cancer	7.43e-06	6.38e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—NOS3—esophageal cancer	7.04e-06	6.05e-05	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—EP300—esophageal cancer	6.94e-06	5.95e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	6.86e-06	5.88e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—HMOX1—esophageal cancer	6.8e-06	5.84e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PTGS2—esophageal cancer	6.8e-06	5.83e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—CYP1B1—esophageal cancer	6.78e-06	5.81e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	6.67e-06	5.73e-05	CbGpPWpGaD
Naproxen—ALB—Hemostasis—PIK3CA—esophageal cancer	6.62e-06	5.69e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—CREBBP—esophageal cancer	6.59e-06	5.66e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—ERBB2—esophageal cancer	6.59e-06	5.66e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—ABCB1—esophageal cancer	6.53e-06	5.6e-05	CbGpPWpGaD
Naproxen—ALB—Hemostasis—TP53—esophageal cancer	6.41e-06	5.5e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—CYP19A1—esophageal cancer	6.37e-06	5.47e-05	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—PIK3CA—esophageal cancer	6.31e-06	5.42e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	6.07e-06	5.21e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	6.03e-06	5.18e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—NOS3—esophageal cancer	5.9e-06	5.06e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—HMOX1—esophageal cancer	5.81e-06	4.99e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	5.7e-06	4.89e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—EP300—esophageal cancer	5.65e-06	4.85e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—CDKN1A—esophageal cancer	5.63e-06	4.83e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—ABCB1—esophageal cancer	5.58e-06	4.79e-05	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—PIK3CA—esophageal cancer	5.5e-06	4.72e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—CREBBP—esophageal cancer	5.36e-06	4.6e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—EP300—esophageal cancer	5.36e-06	4.6e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—CREBBP—esophageal cancer	5.33e-06	4.58e-05	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—PIK3CA—esophageal cancer	5.13e-06	4.4e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	4.94e-06	4.24e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—NOS3—esophageal cancer	4.8e-06	4.12e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—NOS3—esophageal cancer	4.77e-06	4.1e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—MYC—esophageal cancer	4.67e-06	4.01e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—EGFR—esophageal cancer	4.57e-06	3.92e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—EP300—esophageal cancer	4.49e-06	3.85e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PTGS2—esophageal cancer	4.39e-06	3.77e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—PTGS2—esophageal cancer	4.37e-06	3.75e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—CREBBP—esophageal cancer	4.36e-06	3.75e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	4.22e-06	3.62e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PIK3CA—esophageal cancer	4.18e-06	3.59e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—PIK3CA—esophageal cancer	3.96e-06	3.4e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—NOS3—esophageal cancer	3.91e-06	3.35e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—CREBBP—esophageal cancer	3.73e-06	3.2e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—EP300—esophageal cancer	3.65e-06	3.13e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—EP300—esophageal cancer	3.63e-06	3.12e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PTGS2—esophageal cancer	3.57e-06	3.07e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—NOS3—esophageal cancer	3.34e-06	2.87e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—PIK3CA—esophageal cancer	3.32e-06	2.85e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PTGS2—esophageal cancer	3.05e-06	2.62e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—EP300—esophageal cancer	2.97e-06	2.55e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PIK3CA—esophageal cancer	2.7e-06	2.32e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—PIK3CA—esophageal cancer	2.69e-06	2.31e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—EP300—esophageal cancer	2.54e-06	2.18e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PIK3CA—esophageal cancer	2.2e-06	1.89e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PIK3CA—esophageal cancer	1.88e-06	1.61e-05	CbGpPWpGaD
